November 21st, 2023 ProAlt’s therapeutic project named ‘METASTCURE' that has obtained the ‘Seal of Excellence’ label within the Accelerator program of the European Innovation Council has been selected by the Community of Madrid for direct-grant support. The excellence, impact and remarkable potential for success of METASCURE project made it eligible to receive a substantial grant [...]
January 27th, 2023 The collaborative project named ‘Preclinical development and evolution of second-generation antibodies for the treatment of metastatic colorectal cancer’ has been selected to receive funding in the joint ISCIII-CDTI call for proposals in innovation linked to ‘Personalized Medicine and Advanced Therapies’. The multidisciplinary research consortium involves strategic partners like the Group of Mechanisms [...]
The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation. The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product [...]
PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative therapeutic solutions in oncology to top European investors at the EIC Investor Day with CUF. The event took place in Lisbon (Portugal) on 29 and 30 November 2022, where the Company has presented in the ‘Biotech & Pharmaceuticals session’ its antibodies [...]
Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference [...]
PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second discussion panel "Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society" at ASEBIO Investors Day organized by Asociación Española de Bioempresas. The panel was moderated by Carolina Pola, Innovation Strategist at Kaudal, and included reference speakers of the innovation ecosystem [...]
Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]
September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September to the 1st October and will participate in the one-to-one meetings to present to investors and pharma companies the latest results of its anti-cadherins_RGD therapeutic antibodies in oncology. BioSpain is the 10th International Trade Show & Partnering Event that will take [...]
September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]
September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]
Copyright ©2020 Protein Alternatives SL. All rights reserved | Legal Notice & Privacy Policy
